Merck’s Welireg Gets Orphan Pricing Ahead Of Broader RCC Indications
Drug From $1.1bn Peloton Buy Boosts Renal Cancer Franchise
The company set a $26,400 per month list price for the HIF-2α inhibitor in its first US FDA-approved indication of VHL disease-associated tumors, but the drug is being studied in broader populations.
